FONT-SIZE Plus   Neg

Oncolytics Meets Primary Endpoint For First Stage Of Phase 2 Lung Cancer Trial

Oncolytics Biotech Inc. (ONC.TO, ONCY) reported preliminary results from its U.S. Phase 2 trial in patients with squamous cell carcinoma of the lung or SCCLC using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel. The Principal Investigator is Alain Mita of Cedars-Sinai Medical Centre in Los Angeles, CA.

The study's primary objective is to assess the antitumor effect of the treatment regimen in the study population in terms of objective response rates, while the secondary objectives are to assess progression-free survival and overall survival for the treatment regimen in the study population; to determine the proportion of patients receiving the above treatment who are alive and free of disease progression at six months; and to assess the safety and tolerability of the treatment regimen in the study population.

The study is a two stage design, wherein up to 19 evaluable patients with SCCLC were to be treated in the first stage. If four or more patients demonstrated a partial response or better, the study would then proceed to the second stage, with up to 55 patients being treated in the entire study. This endpoint was met after 15 evaluable patients were enrolled. According to the company, five of 15 patients showed partial response, four confirmed, one unconfirmed, and an additional eight patients had stable disease, for 87% disease control rate.

The company said it is proceeding with the second stage of the study.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple confirmed that it has bought face animation software firm Faceshift, although it was tight lipped about how it intends to use the new addition. The move is speculated as a bid to expand into virtual reality. Environment ministry of South Korea Thursday ordered Volkswagen Korea to recall 125,522 diesel vehicles on determining actual emissions of nitrogen oxides. The ministry has asked the German automobile maker to pay a fine of 14.1 billion Won or $12.31 million. The company has to submit a recall plan by January 6, 2016. The U.S. Food and Drug Administration has alerted health care professionals and patients of a voluntary recall of compounded multivitamin capsules containing high amounts of Vitamin D3 (Cholecalciferol), distributed nationwide by Glades Drugs in Pahokee, Florida. FDA has received reports of several...
comments powered by Disqus
Follow RTT